All News
Day 3 EULAR Report
Day 3 was an interesting mix of posters, oral presentations, and review sessions on many practical subjects like osteoarthritis, large vessel vasculitis, systemic sclerosis, and pregnancy. Here are a few of my recommended abstracts from Friday at EULAR 2026.
Read Article
Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials.
Identifying high-risk pts and individualizing tx is paramount.
LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq
Links:
sheila RHEUMarampa ( View Tweet)
#EULAR2026 Updated recommendations on the management of PMR &LVV.
A pleasure to have been part of this huge piece of work, covering 3 distinct conditions, and both diagnosis & management principles.
Watch this space for full guideline coming soon!
#EULAR2026
@RheumNow https://t.co/CUvaQVSU8k
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Do you target #DORIS / remission in #SLE pts
#EULAR2026 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Aiming for #DORIS #SLE #remission
Or #LLDAS in #SLE
Related to ⬆️survival
#deep outcome in RCTs
➡️archived in #deucravacitinib ph2 #LTE
&
ph3 #dapirolizumab & #obintuzimab
-achieved in #CAR-T trials in #lupus
POS0683, 1364, 0695, OP0338
& several 🚗 T abst
#EULAR2026 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
BARI vs TNFi in VTE-enriched #RA pts (RA-BRIDGE + RA-BRANCH, n=3,640, ~3.7 yrs follow-up): VTE non-inferiority not met (HR 1.61, CI 0.97–2.66).
But absolute rates low (2.5% vs 1.7%) and MACE was similar (HR 1.06). Serious infections ↑ with BARI. @RheumNow #EULAR2026 LB0009
Jiha Lee JihaRheum ( View Tweet)
What drives progression to difficult-to-treat RA?
20-year cohort 675pts
-18.8% developed D2T RA
-Younger age, higher HAQ & prior steroid exposure asso w/ D2T RA
-Earlier b/tsDMARD initiation protective
-No diff TNFi vs non-TNFi first-line strategy
Disease severity and https://t.co/SJDv9HCbLv
Aurelie Najm AurelieRheumo ( View Tweet)
LB0002: Sonelokimab (IL-17A/F Nanobody, ~40 kDa) in #axSpA Phase 2: 81% ASAS40 and 54% ASAS partial remission at 12 weeks. Mean ASDAS improvement of −2.0 from baseline. @RheumNow #EULAR2026 https://t.co/TjvtnFPCdj
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Data of #Rituximab
In #SARD-ILD
Small N of #RA-#ILD pts
I think data are sufficient as #RWE of #RTX in RA-ILD
✅benefits in other #CTD ILD
✅benefits in #rheumatoid #arthritis
#EVER-ILD #RCT
HOT #RA-ILD topic June 5
#EULAR2026
@RheumNow https://t.co/61MbsnNsaf
Links:
Janet Pope Janetbirdope ( View Tweet)
Machine learning identifies a “vulnerable” phenotype in older RA patients n=275
-51% “vulnerable”
-Worse grip strength, gait speed & SARC-F
-Higher disability (HAQ 1.56 vs 0.64)
-More fatigue, poorer QoL
-Higher DAS28 despite greater biologic exposure
Suggests we should assess https://t.co/bv1FbTxGKR
Aurelie Najm AurelieRheumo ( View Tweet)
Failure to achieve early remission RA asso w/ non-inflammatory pain
NORD-STAR 526 early RA pts)
no remission at 24 wks increased risk of 48wk
• unacceptable pain (OR ~6)
• refractory pain (OR ~6)
• fibromyalgic RA (OR ~16)
Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw
Aurelie Najm AurelieRheumo ( View Tweet)
Even with tight T2T, ARCTIC 10yr follow-up (n=170) show 9% had RA-ILD on HRCT, plus another 19% with non-specific interstitial findings. Male sex and older age were risk factors. Seropositivity was not. Vigilance remains essential. @RheumNow #EULAR2026 POS1270
Jiha Lee JihaRheum ( View Tweet)
#EULAR2026 POS1355 A cohort study in Japan identified 5-score predictors of GC-free remission in #lupusnephritis: HCQ, pulsed IV GC, Chronicity index=0, =>75% UPCR reduction by 6mo,& 12 mths CRR. Data cutoff 2024. Interested to see impact of current Combo tx from outset @RheumNow https://t.co/qmpgyEyOOV
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
And now does MRI do better than US at predicting RA progression in at risk pts?
Short answer: No likely too sensitive!
130 anti-CCP+ symptomatic pts
36.9% progressed
BL US positivity predicted progression HR 2.8
MRI showed prevalence of subclinical disease synovitis >80%
Aurelie Najm AurelieRheumo ( View Tweet)
Detecting subclinica tenosynovitis in pts at risk for RA: who does it better US or DixonMRI?
65 pts RA CSA, US detected only ~23% of cases identified by Dixon
US misses most! But are they “real” tenosynovitis?
MRI (5-min, no contrast) higher sens
US higher spe
Shall we do https://t.co/stsMRdj9eY
Aurelie Najm AurelieRheumo ( View Tweet)
What does remission really mean to patients with #PsA? The RemiPPsA international qualitative study asked 123 patients across 11 countries. Pain-free + ability to resume daily life topped the list, not just composite scores. #EULAR2026 @RheumNow, POS0294 https://t.co/mEGpkewuTX
Jiha Lee JihaRheum ( View Tweet)
#EULAR2026 POS0172 #Lupus arthritis is the most common domain in RCTs but SLEDAI-MSK or BILAG-MSK isn’t satisfactory. Look out for the role out of LAMDA once externally validated using independent trial datasets. 4 candidates: SJC28, ESR, VAS Phy MSK, & VAS Pa Pain @RheumNow https://t.co/QJ51ETLSSN
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Lung US for RA-ILD screening
Comparison with diagnostic scores
147 RA pts (68 ILD on HRCT)
Asymptomatic cohort
Sens 95.4% Spe 77.7%
Risk scores alone performed poorly.
Combining US + risk scores boosted sensitivity to 100% → promising low-cost screening tool alongside HRCT. https://t.co/7C4zClaxry
Aurelie Najm AurelieRheumo ( View Tweet)
No big surprise here, deucravacitinib does as well without MTX
Pooled analysis of 52wk data of POETYK PSA
Same ACR20/50/70 and MDA response profiles also similar safety profiles
#POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS
Aurelie Najm AurelieRheumo ( View Tweet)
